Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND.: Mastocytosis is characterized by the abnormal proliferation of mast cells in 1 or more organs. In most patients, a mutation is present in the gene for C‐KIT, resulting in deregulation of the c‐kit receptor. Imatinib mesylate is a potent inhibitor of c‐kit receptor tyrosine kinase activity. Therefore, the authors evaluated the efficacy and safety of imatinib mesylate as treatment for patients with systemic mastocytosis. METHODS.: Patients with systemic mastocytosis received imatinib mesylate orally at a dose of 400 mg once daily for 3 to 6 months. Low doses of prednisone were added during the first 2 weeks. Endpoints were reductions in serum tryptase, urinary N‐methylhistamine excretion, skin lesions, the number of mast cells in bone marrow sections, hepatomegaly and/or splenomegaly, and symptoms. RESULTS.: Of 14 patients who were included in the study, 11 patients had the D816V mutation. One patient expressed the FIP1L1‐PDGFR‐α rearrangement gene. In 2 patients, no mutation was found. In 10 patients, serum tryptase levels decreased >20%. In all patients, urinary N‐methylhistamine excretion was reduced. In 8 of 13 evaluable patients, the number of mast cells in the bone marrow decreased. Skin symptoms diminished in 5 of 9 patients. Hepatosplenomegaly improved in 3 of 6 patients. Symptoms decreased in 8 of 13 patients. In all patients who had the D816V mutation, reductions in ≥2 endpoints were achieved. In the patient who expressed the FIP1L1‐PDGFR‐α rearrangement gene, a complete response was attained. In general, imatinib mesylate was tolerated well. CONCLUSIONS.: Imatinib mesylate was effective in patients with systemic mastocytosis, including those who had the D816V mutation. Cancer 2006. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Diagnosis of Mastocytosis by Measurement of Urinary Hist Amine Metabolites
Keyzer, J. J., de Monchy, J. G. R., van Doormaal, J. J., & van Voorst Vader, P. C. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312293092603 · Cited by 179
Cited by
Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149
Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management
Castells, M., & Butterfield, J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.02.002 · Cited by 135
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
Pardanani, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26962 · Cited by 132
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
Ustun, C., DeRemer, D. L., & Akin, C. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.05.006 · Cited by 102
Pardanani, A. (2013) · Blood · doi:10.1182/blood-2013-01-453183 · Cited by 101
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management
Pardanani, A. (2011) · American Journal of Hematology · doi:10.1002/ajh.21982 · Cited by 26
Malik, F., Ali, N., Jafri, S. I. M., Ghani, A., Hamid, M., Boigon, M., & Fidler, C. (2017) · Journal of Medical Case Reports · doi:10.1186/s13256-017-1278-3 · Cited by 3
Metadata
- Authors
- Droogendijk, H. J., Kluin‐Nelemans, H. J. C., van Doormaal, J. J., Oranje, A. P., van de Loosdrecht, A. A., & van Daele, P. L. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-07-05
- Volume
- 107
- Issue
- 2
- Pages
- 345-351
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2137549989
- Cited by
- 147
- References
- 1
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.